The current coronavirus pandemic, COVID-19, has changed our daily lives in the blink of an eye. It has also brought widespread attention back to how the health care system and market dynamics impact how care is...
The current coronavirus pandemic, COVID-19, has changed our daily lives in the blink of an eye. It has also brought widespread attention back to how the health care system and market dynamics impact how care is...
Oncology is changing rapidly as models of care and reimbursement evolve. We have seen this firsthand with the rapid expansion of telehealth services to combat the COVID-19 (coronavirus) pandemic.
This challenge to...
Oncology is changing rapidly as models of care and reimbursement evolve. We have seen this firsthand with the rapid expansion of telehealth services to combat the COVID-19 (coronavirus) pandemic.
This challenge to...
As a community-spread disease, coronavirus 2019 shows us the importance of community—from global, national, state, local, workplace, and individual perspectives.
On March 11, 2020, World Health Organization...
As a community-spread disease, coronavirus 2019 shows us the importance of community—from global, national, state, local, workplace, and individual perspectives.
On March 11, 2020, World Health Organization...
A recent announcement that new biotech start-up, EQRx plans to launch “equivalars,” alternatives to a number of currently patented costly drugs at far lower price points, introduces another disruptive solution trying...
A recent announcement that new biotech start-up, EQRx plans to launch “equivalars,” alternatives to a number of currently patented costly drugs at far lower price points, introduces another disruptive solution trying...
Inclusion of oncology biosimilars in clinical pathways is one approach to reducing costs in this therapeutic area without compromising outcomes for cancer patients. There are currently eight Food and Drug...
Inclusion of oncology biosimilars in clinical pathways is one approach to reducing costs in this therapeutic area without compromising outcomes for cancer patients. There are currently eight Food and Drug...
In this series, we speak with cancer care practitioners about how pathways are being used in their practices, how they are being applied in a particular disease state, and what challenges remain for treatment...
In this series, we speak with cancer care practitioners about how pathways are being used in their practices, how they are being applied in a particular disease state, and what challenges remain for treatment...
This section called “CME Corner,” highlights, when available, relevant continuing medical education (CME) opportunities deemed to be of use to readers. Articles include an overview of a specific area where key...
This section called “CME Corner,” highlights, when available, relevant continuing medical education (CME) opportunities deemed to be of use to readers. Articles include an overview of a specific area where key...
Abstract: In the era of value-based care and constrained resources, oncology practices are increasingly employing advanced practice providers (APPs) to improve practice workflow, increase efficiency, and enable...
Abstract: In the era of value-based care and constrained resources, oncology practices are increasingly employing advanced practice providers (APPs) to improve practice workflow, increase efficiency, and enable...
Abstract: A multidisciplinary team at ChristianaCare, headquartered in Wilmington, DE, designed a comprehensive pathway utilizing an internally developed predictive model to proactively reduce oncology...
Abstract: A multidisciplinary team at ChristianaCare, headquartered in Wilmington, DE, designed a comprehensive pathway utilizing an internally developed predictive model to proactively reduce oncology...
Innovations in precision oncology have helped healthcare providers to create more personalized treatment plans and improve patient outcomes. View this special report to learn more.
Innovations in precision oncology have helped healthcare providers to create more personalized treatment plans and improve patient outcomes. View this special report to learn more.
This supplement aims to raise awareness about non-small cell lung cancer (NSCLC) and its impact on patients by providing comprehensive information to help improve early detection and appropriate care.
This supplement aims to raise awareness about non-small cell lung cancer (NSCLC) and its impact on patients by providing comprehensive information to help improve early detection and appropriate care.
In this product monograph, read an interview with Jeff P. Sharman, MD, as he discusses important BRUKINSA® trial data including efficacy, safety, dosing, administration, and other relevant data. These key findings supported the Food and Drug...
In this product monograph, read an interview with Jeff P. Sharman, MD, as he discusses important BRUKINSA® trial data including efficacy, safety, dosing, administration, and other relevant data. These key findings supported the Food and Drug...
This review summarizes the diagnosis, pathophysiology, and evidence-based guidelines for the prevention and management of tumor lysis syndrome, a common, acute, life-threatening disease primarily in patients with hematologic cancers and solid...
This review summarizes the diagnosis, pathophysiology, and evidence-based guidelines for the prevention and management of tumor lysis syndrome, a common, acute, life-threatening disease primarily in patients with hematologic cancers and solid...
In an interview with Journal of Clinical Pathways, Nicholas Short, MD, shares objectives on the design and benefits of MD Anderson’s Tumor Lysis Syndrome clinical assessment for patient risk and impact on patient care.
In an interview with Journal of Clinical Pathways, Nicholas Short, MD, shares objectives on the design and benefits of MD Anderson’s Tumor Lysis Syndrome clinical assessment for patient risk and impact on patient care.
Updated multiple times in 2022, the National Comprehensive Cancer Network (NCCN) Guidelines for B-Cell Lymphomas provide recommendations for the prevention, diagnosis, and management of malignancies.
Updated multiple times in 2022, the National Comprehensive Cancer Network (NCCN) Guidelines for B-Cell Lymphomas provide recommendations for the prevention, diagnosis, and management of malignancies.
In an interview with Journal of Clinical Pathways, Mitul Gandhi, MD, reviews the clinical impact and treatment approaches and challenges for patients with marginal zone lymphoma and Waldenström’s macroglobulinemia.
In an interview with Journal of Clinical Pathways, Mitul Gandhi, MD, reviews the clinical impact and treatment approaches and challenges for patients with marginal zone lymphoma and Waldenström’s macroglobulinemia.
The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...
The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...
NCCN released updates to its practice guidelines on treating triple-negative breast cancer, featuring updates on sacituzumab govitecan recommendations and more.
NCCN released updates to its practice guidelines on treating triple-negative breast cancer, featuring updates on sacituzumab govitecan recommendations and more.